BioRem (CVE:BRM) Upgraded by Cormark to “Moderate Buy” Rating

BioRem (CVE:BRM) was upgraded by Cormark to a “moderate buy” rating in a research report issued on Tuesday,Zacks.com reports.

BioRem Stock Down 0.6 %

CVE:BRM traded down C$0.02 on Tuesday, hitting C$3.10. The stock had a trading volume of 5,650 shares, compared to its average volume of 32,588. The company has a quick ratio of 1.08, a current ratio of 1.57 and a debt-to-equity ratio of 48.97. The business’s fifty day moving average is C$2.82 and its 200 day moving average is C$2.40. BioRem has a 52 week low of C$0.95 and a 52 week high of C$3.39. The company has a market cap of C$48.67 million, a PE ratio of 14.76 and a beta of 0.85.

Insider Activity

In related news, Director Derek Webb sold 120,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of C$2.93, for a total value of C$351,600.00. Insiders own 1.90% of the company’s stock.

BioRem Company Profile

BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs.